Skip to main content
ANAB
NASDAQ Life Sciences

Officer Dennis Mulroy Files to Sell Additional $1.15M in Stock, Continuing Recent Trend

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$56.473
Mkt Cap
$1.732B
52W Low
$11.402
52W High
$72.36
52W Position info
395% above low
Off High info
22% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $11.402.

Summary

AnaptysBio officer Dennis Mulroy has filed to sell an additional $1.15 million in company stock, extending a recent pattern of significant insider sales totaling over $17 million in the last three months.


Key Events · Ownership and Investor Activity · ANAB

  • Officer Files Intent to Sell

    Dennis Mulroy, an officer at AnaptysBio, has filed a Form 144 indicating intent to sell 20,000 shares of common stock, with an approximate market value of $1.15 million.

  • Continuation of Sales Pattern

    This filing extends a recent trend of significant sales by Mr. Mulroy, who has sold a total of 297,900 shares for gross proceeds of over $16.1 million in the past three months, bringing his total sales (including this filing) to over $17.2 million.

  • Shares Acquired via Option Exercise

    The shares intended for sale were acquired through a stock option exercise, a common method for officers to monetize compensation.

  • Context of Share Repurchase Program

    These ongoing officer sales occur while the company has an active $100 million share repurchase program, announced in May 2026, which could be seen as conflicting signals regarding management's view on valuation.


Analysis · ANAB · Life Sciences

This Form 144 indicates an officer's intent to sell a substantial amount of company stock, adding to a pattern of significant insider sales. While the shares are acquired through option exercises, the continuous disposition of over $17 million in stock by a single officer over three months, especially when the company has a share repurchase program, can be interpreted negatively by investors. It suggests a lack of conviction in the stock's near-term appreciation from a key insider.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANAB was trading at $56.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Nov 18, 2026, 7:03 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $47.74
Real-time Price: $47.40 info
Change: -$0.340 (-0.71%) info
Market Cap: $1.409B info
ANAB
Nov 18, 2026, 6:56 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $47.06
Real-time Price: $47.40 info
Change: +$0.340 (+0.72%) info
Market Cap: $1.409B info
ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.40 info
Change: -$0.370 (-0.77%) info
Market Cap: $1.409B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.40 info
Change: -$0.370 (-0.77%) info
Market Cap: $1.409B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $47.40 info
Change: +$2.40 (+5%) info
Market Cap: $1.409B info